thr-317
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2016 (NCT03071068)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Placenta growth factorINHIBITOR
PGF inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- thr-317
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03669393 | Phase 2 | Sep 30, 2018 | Oxurion NV. |
| NCT03499223 | Phase 2 | Apr 20, 2018 | Oxurion NV. |
| NCT03071068 | Phase 2 | Dec 1, 2016 | Oxurion NV. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Oxurion NV. | For profit | 3 | 3 | 1 | 2016 |
1 organizations
Page 1 / 1